The correlation of SIPL1 expression with poor survival for patients with PR+ or ER+ breast cancer does not exclude the possible contributions of SIPL1 to the tumorigenesis of HER2+ and triple negative breast cancer, as gain of the SIPL1 gene and increases in the SIPL1 mRNA were demonstrated in these BC types in comparison with normal breast tissues. This evidence concerns the gene SHARPIN and breast cancer.